Clinical Trials Logo

Multiple Sclerosis clinical trials

View clinical trials related to Multiple Sclerosis.

Filter by:

NCT ID: NCT04233970 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis

POWER@MS2
Start date: February 17, 2020
Phase: N/A
Study type: Interventional

This randomized controlled trial will evaluate a web-based relapse management programme, which is easily accessible for people with multiple sclerosis. The trial is accompanied by a mixed-methods process evaluation and a health economic evaluation. It is expected that the programme will positively change patients' relapse management and strengthen their autonomy and participation.

NCT ID: NCT04231253 Completed - Multiple Sclerosis Clinical Trials

MUltiple Sclerosis : T Cell / B Cell Exploration

MUST-BE
Start date: February 25, 2019
Phase:
Study type: Observational

This study, an ancillary to ABCD-SEP (NCT03744351), will be interested in more precisely characterizing circulating and infiltrating TH cells in Multiple Sclerosis whether at the transcriptomic level or at the functional level.

NCT ID: NCT04228328 Completed - Multiple Sclerosis Clinical Trials

Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis

VR6minWT6
Start date: March 3, 2020
Phase:
Study type: Observational

The objective of this study is to validate a different version of the 6 minutes Walk Test (6minWT), the 6minWT on 6 meters, instead of the 30 meters. The secondary objectives are to verify the reliability of this new version and to analyze the possible differences between the 6minWT6 and the 6minWT30 (according to speed at half-turn, other parameters: age, gender, height, EDSS score, type of disease, time since relapse).

NCT ID: NCT04221191 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP

TEC-ADHERE
Start date: August 19, 2019
Phase:
Study type: Observational

The primary objective is to compare oral dimethyl fumarate (DMF) persistence at six months in relapsing-remitting multiple sclerosis (RR-MS) participants initiating DMF with and without OroSEP patient support program (PSP), respectively. The secondary objectives are: to compare oral DMF persistence at one month and three months in RR-MS participants initiating DMF with and without OroSEP PSP, respectively; To compare oral DMF adherence at six months in RR-MS participants initiating DMF with and without OroSEP PSP; To compare at three months and six months the reason of oral DMF discontinuation, in the two groups; To describe the percentage of participants with treatment-related adverse events globally and by class of adverse events, in the two groups of participants; To assess the evolution of participants' anxiety globally and to compare it at inclusion and at six months in participants with and without OroSEP PSP, respectively; To describe participants' satisfaction regarding oral DMF initiation and follow-up globally at six months and to compare it in patients with and without OroSEP PSP, respectively; For OroSEP PSP group: To assess participants' satisfaction regarding their participation in OroSEP PSP at six months; To assess neurologists' satisfaction regarding their participation in OroSEP PSP, after the last participant last visit of center.

NCT ID: NCT04217564 Completed - Multiple Sclerosis Clinical Trials

Nutritional Counselling for Patients at Kasr AlAiny Multiple Sclerosis Clinic: an Intervention Study

AlAiny
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Eligible Multiple sclerosis patients attending Kasr AlAiny Multiple Sclerosis Clinic will be randomly allocated to either the intervention or control group by randomized block design. Patients in the 2 groups will be initially assessed. Those in the intervention group will receive a counselling session then instructed on the subsequent follow up dates. Those in the control group will not receive nutritional counselling during the study period but will be instructed to attend for final assessment by the end of the study. Apart from counselling, patients will receive the same care from the clinic medical staff. After the final assessment the control group will be invited to receive the nutritional counselling material to gain its suspected benefits.

NCT ID: NCT04215354 Completed - Multiple Sclerosis Clinical Trials

Association Between Fatigue and Balance in Patients With Multiple Sclerosis

Start date: September 2014
Phase: N/A
Study type: Interventional

The relationship between fatigue and balance was established. Fatigue was correlated with 8 parameters of balance scales. Moreover, there was a strong correlation between the level of fatigue from one side and depression, quality of life and disease severity from the other side.Fatigue seems to be the main problem in patients with MS which may influence other signs and symptoms such as balance.

NCT ID: NCT04211740 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Phase II Clinical Trial of OCH-NCNP1

Start date: December 6, 2019
Phase: Phase 2
Study type: Interventional

This study is designed to assess the efficacy and safety of OCH-NCNP1 compared to placebo in subjects diagnosed with relapsing remitting multiple sclerosis (RRMS) and secondary progressive mltiple sclerosis (SPMS) .

NCT ID: NCT04202055 Completed - Multiple Sclerosis Clinical Trials

Immunologic Biomarker Profile of Cerebrospinal Fluid

BIOMOG
Start date: January 2, 2018
Phase:
Study type: Observational

The aim of this study was the describe the Immunologic biomarker profile of cerebrospinal fluid in multiple sclerosis patients

NCT ID: NCT04201691 Completed - Multiple Sclerosis Clinical Trials

Effect of Manuel Therapy on Tonus, Proprioseption and Balance in Multiple Sclerosis

Start date: January 7, 2020
Phase: N/A
Study type: Interventional

This study is investigates the effect of cervical mobilization on tonus, position sense and balance in patient with multiple sclerosis. Half of participants will received classic rehabilitation program, while the other half will received servical mobilization in addition to classic rehabilitation program.

NCT ID: NCT04201470 Completed - Multiple Sclerosis Clinical Trials

Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis

AMIS
Start date: December 9, 2019
Phase: N/A
Study type: Interventional

Idiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common. Besides multiple sclerosis, other distinct disorders including for example anti-AQP4 (aquaporine-4) and anti-MOG (Myelin oligodendrocyte glycoprotein) NMOSD (Neuromyelitis optica spectrum disorder) have been well characterized and are now known to be distinct from MS. some patient belonging to MS spectrum have recently being characterized but unusual MRI findings have mimicking inherited leukoencephalopathies and leukodystrophies. Whether these patients with atypical phenotype represent a separate disease distinct from MS or belong to MS spectrum is not clear. The objectives are to evaluate a series of 15 patients with atypical forms of MS using non-conventional MRI techniques and biological biomarkers (serum neurofilaments light chain) and to compare them with classical MS patients (15 relapsing remitting patients and 15 progressive patients) and 15 controls. the hypothesize is that these patients with atypical MS have a more severe neurodegenerative process.